Published in Immunochemistry on July 01, 1974
Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A (1977) 5.23
Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci U S A (1978) 4.43
Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. J Exp Med (1975) 3.12
Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med (1977) 2.87
Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med (1976) 2.66
Requirements for the solubilization of immune aggregates by complement: assembly of a factor B-dependent C3-convertase on the immune complexes. J Exp Med (1977) 1.79
Multiple sedimenting species of properdin in human serum and interaction of purified properdin with the third component of complement. J Exp Med (1976) 1.58
The binding of human complement proteins C5, factor B, beta 1H and properdin to complement fragment C3b on zymosan. Biochem J (1981) 1.40
Assembly of the cytolytic alternative pathway of complement from 11 isolated plasma proteins. J Exp Med (1978) 1.20
Metabolism of properdin in normal subjects and patients with renal disease. J Clin Invest (1975) 1.09
Clinical significance of serum properdin levels and properdin deposition in the dermal-epidermal junction in systemic lupus erythematosus. J Clin Invest (1976) 1.00
Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products. Biochem J (1988) 0.98
Resolution and analysis of 'native' and 'activated' properdin. Biochem J (1987) 0.98
Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement. Biochem J (1988) 0.85
Characterization of the human properdin gene. Biochem J (1992) 0.82
Bacterial factors chemotactic for polymorphonuclear leukocytes. Am J Pathol (1968) 5.77
Properties of highly purified human properdin. J Immunol (1968) 3.96
Functional relationship of factor B in the properdin system to C3 proactivator of human serum. J Immunol (1971) 3.81
Complement as a mediator of inflammation. II. Biological properties of anaphylatoxin prepared with purified components of human complement. J Exp Med (1967) 3.05
Glomerular and dermal depostion of properdin in systemic lupus erythematosus. N Engl J Med (1972) 2.01
Anaphylatoxin formation by purified human C'1 esterase. J Immunol (1965) 1.80
The relationship of glycine-rich -glycoprotein to factor B in the properdin system and to the cobra factor-binding protein of huan serum. J Exp Med (1973) 1.80
Host defense against Neisseria meningitidis requires a complement-dependent bactericidal activity. Science (1979) 1.62
Multiple sedimenting species of properdin in human serum and interaction of purified properdin with the third component of complement. J Exp Med (1976) 1.58
In vitro induction of cytologic and functional differentiation of the immature human monocytelike cell line U-937 with phorbol myristate acetate. Am J Pathol (1985) 1.34
Gross and ultrastructural observations on lesions produced by intradermal injection of human C3a in man. Am J Pathol (1970) 1.32
Solid phase radioimmunoassay of properdin. Immunochemistry (1973) 1.25
Cleavage of the fourth component of human complement (C4) by activated Cls. Immunochemistry (1970) 1.16
Clevage of human Clś by human lysosomal enzymes, plasmin, and trypsin. Immunochemistry (1971) 1.14
Metabolism of properdin in normal subjects and patients with renal disease. J Clin Invest (1975) 1.09
STUDIES ON IMMUNE HUMAN HEMOLYSIS : II. THE DONATH-LANDSTEINER REACTION AS A MODEL SYSTEM FOR STUDYING THE MECHANISM OF ACTION OF COMPLEMENT AND THE ROLE OF C'1 AND C'1 ESTERASE. J Exp Med (1961) 1.05
Selective deficiency of the second component of complement in a patient with anaphylactoid purpura. Clin Immunol Immunopathol (1975) 1.03
Systemic lupus erythematosus in a patient with C4 deficiency. J Rheumatol (1982) 0.98
Selective deficiency of the fourth component of complement in a patient with systemic lupus erythematosus (SLE): immunochemical and biological studies. Clin Exp Immunol (1981) 0.97
Chemotactic migration of leucocytes through corneal layers: an in vitro study. Can J Ophthalmol (1976) 0.95
Biosynthesis of a single chain pro-C5 by normal mouse liver mRNA: analysis of the molecular basis of C5 deficiency in AKR/J mice. J Immunol (1979) 0.94
Kinetic studies on the fragmentation of the third component of complement (C3) by trypsin. J Immunol (1977) 0.92
A simple one-step hemolytic assay for C2 with C2-deficient human serum. J Immunol (1977) 0.91
C3 deposition in cholesterol-induced atherosclerosis in rabbits: a possible etiologic role for complement in atherogenesis. J Immunol (1979) 0.89
Purification of native properdin by reversed affinity chromatography and its activation by proteolytic enzymes. J Immunol (1976) 0.88
Inherited deficiency of properdin and C2 in a patient with recurrent bacteremia. Am J Med (1987) 0.88
The role of sialic acid in the functional activity and the hepatic clearance of C1-INH. J Immunol (1981) 0.88
Requirement for complement components and fibrinogen in the zymosan-induced release reaction of human blood platelets. J Immunol (1974) 0.87
Captopril--a potential free radical scavenger: inhibition of PMN NADPH oxidase. Clin Invest Med (1988) 0.85
Disorders of the complement system in lipodystrophy. Clin Immunol Immunopathol (1977) 0.85
A re-examination of the ability of pFc' and Fc' to participate in passive cutaneous anaphylaxis. Immunochemistry (1972) 0.85
Acute inflammation induced by immune complexes in the microcirculation. Exp Mol Pathol (1985) 0.84
Cleavage of human C5 by trypsin: characterization of the digestion products by gel electrophoresis. J Immunol (1977) 0.83
Changes in the immunochemical properties of highly purified properdin in human serum. J Immunol (1975) 0.83
Interactions of antirheumatic drugs with the superoxide generation system of activated human polymorphonuclear leukocytes. J Rheumatol (1986) 0.82
Immunological, structural and functional relationships between an anti-complementary protein from Crotalus atrox venom, cobra venom factor and human C3. Immunology (1980) 0.82
Effects in the rat of intradermal injection of purified proteinases from streptococcus and Serratia marcescens. Proc Soc Exp Biol Med (1975) 0.82
Presidential address to American Association of Immunologists in Anaheim, California, April 16, 1980. Louis Pillemer, Properdin, and scientific controversy. J Immunol (1980) 0.81
Pathways to the complement system. N Engl J Med (1972) 0.81
The complement system and inflammation. Curr Top Pathol (1979) 0.81
Structural features and biologic properties of fragments obtained by limited proteolysis of C3. J Immunol (1976) 0.81
Chemotactic responsiveness and random motility of polymorphonuclear leukocytes from patients with progressive systemic sclerosis. J Rheumatol (1985) 0.80
Some nonsteroidal antiinflammatory drugs inhibit the generation of superoxide anions by activated polymorphs by blocking ligand-receptor interactions. J Rheumatol (1985) 0.80
Observations on the effects of a proteinase from Serratia marcescens on the third component of human complement. Am J Med Sci (1972) 0.80
Granule enzymes from human leukocytes: their effect on HeLa cells. Proc Soc Exp Biol Med (1974) 0.80
Purification and characterization of a single chain precursor C3-protein (pro-C3) from normal human plasma. J Immunol (1979) 0.79
A selective and complete absence of C1q in a patient with vasculitis and nephritis. Clin Immunol Immunopathol (1982) 0.79
Inherited C8 beta subunit deficiency in a patient with recurrent meningococcal infections: in vivo functional kinetic analysis of C8. Clin Exp Immunol (1985) 0.79
Effect on the human complement system of the major non-steroidal anti-inflammatory drugs: aspirin, indomethacin, phenylbutazone, oxyphenbutazone and sulindac. Clin Exp Immunol (1983) 0.79
Purification, characterization and analysis of the mechanism of action of four anti-complementary factors in Crotalus atrox venom. Immunochemistry (1977) 0.78
Interaction of Crotalus atrox venom with serum complement: kinetic analysis. Immunochemistry (1977) 0.78
Effect of proteolytic digestion on the structure and function of human properdin. J Immunol (1976) 0.78
The effects of heat, pH and chemical agents on the functional activity of properdin. Immunochemistry (1978) 0.78
Processing of human factor I in COS-1 cells co-transfected with factor I and paired basic amino acid cleaving enzyme (PACE) cDNA. Mol Immunol (1995) 0.78
An initiator element and a proximal cis-acting sequence are essential for transcriptional activation of the complement factor I (CFI) gene. Gene (1999) 0.77
In vitro studies on the biosynthesis of rabbit C3: evidence for the synthesis of a nascent single chain precursor C3. J Immunol (1979) 0.77
Neutrophil function in the immotile cilia syndrome. J Lab Clin Med (1982) 0.77
Production of antiserum to human properdin and demonstration of antigenic differences between the native and activated protein. Proc Soc Exp Biol Med (1976) 0.77
Distribution and levels of properdin in human body fluids. Clin Immunol Immunopathol (1976) 0.77
Proteolysis of C2 and factor B: analyses of cleavage products by one- and two- dimensional peptide mapping. Mol Immunol (1981) 0.77
Migration of porcine endothelial and smooth muscle cells in response to platelet-associated factors. Am J Hematol (1984) 0.77
Glomerulonephritis with mesangial deposits of IgA unassociated with systemic disease. Can Med Assoc J (1976) 0.77
The crisis of the peer review system. Fed Proc (1973) 0.75
Chemical and immunological characterization of the electrophoretic components of the Fc fragment of human immunoglobulin G. Immunochemistry (1972) 0.75
Stability of immune serum globulin during storage: effects of modifications in the fractionation scheme. Vox Sang (1969) 0.75
IgA nephritis unassociated with systemic disease. Am Heart J (1977) 0.75
Cloning and characterization of the non-catalytic heavy chain of mouse complement factor I gene: structure comparison with the human homologue. Biochem Mol Biol Int (1999) 0.75
Inhibition of vitamin D2-induced arteriosclerosis in rats by depletion of complement with cobra venom factor. Artery (1980) 0.75
Purification and quantitation of the components of the alternative complement pathway. Methods Enzymol (1983) 0.75
A radial hemolysis method in agarose for the functional assay of properdin. J Immunol Methods (1978) 0.75
Modulation of phospholipid methylation in rabbit leukocytes by indomethacin. Inflammation (1986) 0.75
Panel Discussion on Purification of Biologic Products : Problems Encountered in the Purification of Toxoids. Am J Public Health Nations Health (1950) 0.75
The anticomplementary activity of the rabbit lens. Can J Ophthalmol (1979) 0.75
Anticomplementary activity of cornea, vitreous and chorioretina in rabbits. Can J Ophthalmol (1979) 0.75
Complement activation in semi-solid medium: Insolubilization of properdin and the third component of complement (C3) in agar gels. J Immunol (1976) 0.75
Corporate support of medical education. Bull N Y Acad Med (1983) 0.75
Electro-immunoassay for properdin. A comparison with the radioimmunoassay. Clin Immunol Immunopathol (1976) 0.75
Effects of anti-inflammatory and anti-rheumatic drugs on the activities of purified and membrane-bound Na+/K+ adenosine triphosphatase. Immunopharmacology (1985) 0.75